Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003524 | 0.88 | IDO1 (0.31) | ALDH1A1HTTSMN1; SMN2L3MBTL1IDO1 | |
| SCHEMBL26771643 | 0.85 | NR1I2 (0.36) | ALDH1A1HTTSMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL25718332 | 0.83 | IDO1 (0.32) | ALDH1A1HTTSMN1; SMN2L3MBTL1IDO1 | |
| SCHEMBL15304182 | 0.81 | ALDH1A1 (0.36) | ALDH1A1HTTSMN1; SMN2L3MBTL1IDO1 | |
| SCHEMBL24919732 | 0.81 | ALDH1A1 (0.36) | ALDH1A1HTTSMN1; SMN2L3MBTL1IDO1 | |
| SCHEMBL17018452 | 0.79 | SLC6A4 (0.37) | ALDH1A1HTTSMN1; SMN2L3MBTL1IDO1 | |
| SCHEMBL3466744 | 0.79 | SLC6A4 (0.37) | ALDH1A1HTTSMN1; SMN2L3MBTL1IDO1 | |
| Hydrochloric Acid SCHEMBL27164845 | 0.78 | SLC6A4 (0.36) | ALDH1A1HTTSMN1; SMN2L3MBTL1IDO1 | |
| SCHEMBL18948523 | 0.77 | NR1I2 (0.36) | ALDH1A1HTTSMN1; SMN2L3MBTL1OPRM1 | |
| SCHEMBL23172210 | 0.77 | NR1I2 (0.36) | ALDH1A1HTTSMN1; SMN2L3MBTL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | ALDH1A1 433/4885HTT 322/4885SMN1; SMN2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.